BioSyent CEO sells shares to institutional shareholder

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Hosted EventsThe Future of Credit and Risk Management: Trends, Challenges, and Opportunities in Europe
- 03/28/2023
- CIRCL, Amsterdam
- 08:30 - 13:00 Central European Time
WebinarPractical steps to achieve net-zero underwriting – Set a baseline, define targets and take action
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am GMT
WebinarPolitics & Policy: Sustainability Measures and Physical Risks
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

Blog

A Cloud Migration Plan for Corporations featuring Snowflake®

Blog

Investor Activism Campaigns Hit Record High in 2022

Blog

Essential IR Insights Newsletter - February 2023

13 Dec, 2016 | 18:04

Author Mirza Salam Ahmed
Theme Healthcare & Pharmaceuticals

BioSyent Inc.'s President and CEO Rene Goehrum sold 300,000 shares of the company to an existing institutional shareholder in a non-open market transaction.

Goehrum still holds 2,245,261 shares of the company, either directly or indirectly, and is the largest shareholder of BioSyent.